Israel Englander Nurix Therapeutics, Inc. Transaction History

Millennium Management LLC

$199 Billion
Q3 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 221,718 shares of NRIX stock, worth $4.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

221,718

Previous 599,623 63.02%

Holding current value

$4.4 Million

Previous $12.5 Million 60.23%

% of portfolio

0.0%

Previous 0.01%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$18.93 - $25.69 $7.15 Million - $9.71 Million	-377,905 Reduced 63.02%	221,718 $4.98 Million
Q2 2024 Aug 14, 2024	BUY	$12.02 - $21.3 $2.71 Million - $4.8 Million	225,374 Added 60.22%	599,623 $12.5 Million
Q1 2024 May 15, 2024	SELL	$7.77 - $15.66 $25,944 - $52,288	-3,339 Reduced 0.88%	374,249 $5.5 Million
Q4 2023 Feb 14, 2024	SELL	$4.25 - $10.71 $1.13 Million - $2.86 Million	-266,823 Reduced 41.41%	377,588 $3.9 Million
Q2 2023 Aug 14, 2023	BUY	$8.7 - $13.28 $1.59 Million - $2.43 Million	182,819 Added 39.61%	644,411 $6.44 Million
Q1 2023 May 15, 2023	SELL	$8.56 - $13.26 $733,960 - $1.14 Million	-85,743 Reduced 15.67%	461,592 $4.1 Million
Q4 2022 Feb 14, 2023	SELL	$9.86 - $14.59 $1.9 Million - $2.81 Million	-192,590 Reduced 26.03%	547,335 $6.01 Million
Q3 2022 Nov 14, 2022	SELL	$12.33 - $19.81 $887,796 - $1.43 Million	-72,003 Reduced 8.87%	739,925 $9.64 Million

Others Institutions Holding NRIX

# of Institutions

181

Shares Held

68.1M

Call Options Held

78K

Put Options Held

53.8K

View Full List

About Nurix Therapeutics, Inc.

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $935M
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

More about NRIX

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account